NCT07014202View on ClinicalTrials.gov

Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

June 11, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
COMBINATION_PRODUCT

Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy

Immunotherapy (with or without chemotherapy) maintenance therapy combined with radiotherapy in patients with advanced NSCLC who have not progressed after 4-6 cycles of first-line platinum-containing chemotherapy combined with immunotherapy and who have an oligo-residual status confirmed by PETCT.

DRUG

Immunotherapy (with or without chemotherapy) maintenance therapy

Immunotherapy (with or without chemotherapy) maintenance therapy in patients with advanced NSCLC who have not progressed after 4-6 cycles of first-line platinum-containing chemotherapy combined with immunotherapy and who have an oligo-residual status confirmed by PETCT.

Trial Locations (1)

100021

RECRUITING

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER